Stocks · Healthcare · Biotechnology
Viking Therapeutics, Inc. VKTX
$29.28 -2.20% Close, Oct 5, 2026 · NASDAQ · Market cap $3.49B
Next earnings report: Oct 28, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The company holds net cash of $121.7M (cash above total debt).
- The stock is 31% below its highest close of the past year.
- The diluted share count rose 3.4% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
How fast revenue, earnings and cash flow are growing.
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 6%
- Accruals (lower is better)Top 11%
- Interest coverBottom 1%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 38%
- Free-cash-flow yieldBottom 34%
- EBITDA / enterprise valueBottom 31%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 48%
- 6-month returnBottom 28%
- 1-year return vs S&P 500Bottom 46%
- Distance from 52-week highBottom 49%
- Trend checklist (0–4)Bottom 36%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 20%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyTop 21%
- Upside to consensus price targetTop 16%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 17%
- Maximum drawdown, 3 yearsBottom 35%
- Beta vs S&P 500 (lower is better)Top 44%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Return on invested capital | -135.8% | — | Bottom 6% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -22.3%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -70002.6×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.09%
- Shareholder yield
- -0.09%
- Share count change, 1 year
- +3.4%
- Share count change, 3-year CAGR
- +5.4%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Jul 29, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 2 of 8
- Average EPS surprise, last 4
- -24.0%
- Average 2-day reaction, last 8
- -0.5%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $98.20
- Target vs current price
- +235.4%
- Analysts with a rating
- 24
- Share rating Buy or Strong Buy
- 96%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 29, 2026 | +10.6% | -1.3% | -2.7% | +0.9% | — |
| Apr 29, 2026 | -35.6% | -3.3% | -3.3% | -2.3% | +7.4% |
| Feb 11, 2026 | -55.1% | -0.7% | +4.9% | +24.4% | +9.8% |
| Oct 22, 2025 | -15.7% | -4.7% | +5.9% | +14.5% | +2.9% |
| Jul 23, 2025 | -31.8% | +4.0% | +2.5% | -24.1% | +9.4% |
| Apr 23, 2025 | -20.6% | +1.2% | +9.7% | +12.5% | +25.6% |
| Feb 5, 2025 | -14.3% | +3.5% | -7.4% | -13.7% | -11.6% |
| Oct 23, 2024 | +8.3% | -2.6% | +18.2% | -17.0% | -47.0% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 29, 2026 | -$1.10 | -$1.23 | +10.6% | — |
| Apr 29, 2026 | -$1.37 | -$1.01 | -35.6% | — |
| Feb 11, 2026 | -$1.38 | -$0.89 | -55.1% | — |
| Oct 22, 2025 | -$0.81 | -$0.70 | -15.7% | — |
| Jul 23, 2025 | -$0.58 | -$0.44 | -31.8% | — |
| Apr 23, 2025 | -$0.41 | -$0.34 | -20.6% | — |
| Feb 5, 2025 | -$0.32 | -$0.28 | -14.3% | — |
| Oct 23, 2024 | -$0.22 | -$0.24 | +8.3% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -11.98% | — | — | Bottom 34% |
| Earnings yield | -15.92% | — | — | Bottom 38% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -6.2%
- 200-day average slope (20 days)
- -1.1%
- Distance from 50-day average
- -11.9%
- Distance from 200-day average
- -11.6%
- RSI (14)
- 40.7
- Relative volume
- 0.77×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 81.9%
- Volatility vs own 5-year history
- 68th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.00
- Correlation with S&P 500
- 0.22
- Current drawdown from 1-year high
- -30.5%
- Maximum drawdown, 3 years
- -78.9%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 28, 2024 | Apr 8, 2025 | -78.9% | 278 days | Not yet recovered |
| Feb 5, 2021 | Jun 16, 2022 | -78.2% | 343 days | 161 days (Feb 7, 2023) |
| Jun 8, 2023 | Oct 27, 2023 | -62.7% | 98 days | 70 days (Feb 8, 2024) |
| Mar 17, 2023 | Mar 24, 2023 | -25.2% | 5 days | 2 days (Mar 28, 2023) |
| May 16, 2023 | May 30, 2023 | -16.3% | 9 days | 7 days (Jun 8, 2023) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $3.49B
- EPS, diluted (TTM)
- -$4.66
- Revenue (TTM)
- $0
- 52-week range
- $25.77 – $43.15
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | -$431,000 |
| Operating income | -$55.7M | -$70.4M | -$100.8M | -$150.9M | -$393.3M |
| Net income | -$55.0M | -$68.9M | -$85.9M | -$110.0M | -$359.6M |
| EPS (diluted) | -$0.70 | -$0.88 | -$0.91 | -$1.01 | -$3.19 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$24.9M | -$35.4M | -$45.6M | -$65.6M | -$90.8M | -$157.7M | -$158.3M | -$128.0M |
| EPS (diluted) | -$0.22 | -$0.32 | -$0.41 | -$0.58 | -$0.81 | -$1.38 | -$1.37 | -$1.10 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$47.6M | -$48.4M | -$73.4M | -$87.8M | -$278.7M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | -$47.6M | -$48.4M | -$73.4M | -$87.8M | -$278.7M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $7.6M | -$6.8M | $269.8M | $597.1M | $2.5M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $501.7M
- Total assets
- $521.9M
- Total liabilities
- $113.6M
- Total debt
- $4.1M
- Net debt
- -$121.7M
- Shareholders’ equity
- $408.3M
As of Jun 30, 2026 (filed Jul 29, 2026).
Short interest
- Shares sold short
- 22,583,758
- Days to cover
- 12.32
- Change vs previous report
- +1.8%
FINRA short interest, settlement date Sep 15, 2026.